CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer.

CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer. PLoS One. 2015; 10(9):e0139237.

View in: PubMed

subject areas

Animals
Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Cell Line, Tumor
Disease Models, Animal
Disease Progression
Drug Resistance, Neoplasm
Female
Gene Expression Regulation, Neoplastic
Human Umbilical Vein Endothelial Cells
Mice, Nude
Neovascularization, Pathologic
Niacinamide
Ovarian Neoplasms
Phenotype
Phenylurea Compounds
Receptors, Interleukin-8B
Vascular Endothelial Growth Factor A
Xenograft Model Antitumor Assays

authors with profiles

Ankur Sharma